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Diabetes mellitus (DM) is an important risk factor for atherothrombosis.1 Despite advances in the treatment 
of both DM and cardiovascular disease, patients with DM 
are not only at increased risk for cardiovascular events but 
also have greater morbidity and mortality when such events 
occur.2,3 As the global population becomes more sedentary 
and obesity becomes more common, the prevalence of DM is 
increasing and is likely to continue to do so. As a result, the 
attributable risk for atherothrombotic events associated with 
DM is increasing.4
Editorial see p 1041 
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The association between DM and atherothrombosis is likely 
multifactorial.4 At least in part, enhanced platelet reactivity 
is believed to predispose patients with DM to thrombosis.5,6 
Background—Vorapaxar reduces cardiovascular death, myocardial infarction (MI), or stroke in patients with previous MI 
while increasing bleeding. Patients with diabetes mellitus (DM) are at high risk of recurrent thrombotic events despite 
standard therapy and may derive particular benefit from antithrombotic therapies. The  Thrombin Receptor Antagonist 
in Secondary Prevention of Atherothrombotic Ischemic Events-TIMI 50 trial was a randomized, double-blind, placebo-
controlled trial of vorapaxar in patients with stable atherosclerosis.
Methods and Results—We examined the efficacy of vorapaxar in patients with and without DM who qualified for the trial 
with a previous MI. Because vorapaxar is contraindicated in patients with a history of stroke or transient ischemic attack, 
the analysis (n=16 896) excluded such patients. The primary end point of cardiovascular death, MI, or stroke occurred more 
frequently in patients with DM than in patients without DM (rates in placebo group: 14.3% versus 7.6%; adjusted hazard 
ratio, 1.47; P<0.001). In patients with DM (n=3623), vorapaxar significantly reduced the primary end point (11.4% versus 
14.3%; hazard ratio, 0.73 [95% confidence interval, 0.60–0.89]; P=0.002) with a number needed to treat to avoid 1 major 
cardiovascular event of 29. The incidence of moderate/severe bleeding was increased with vorapaxar in patients with DM 
(4.4% versus 2.6%; hazard ratio, 1.60 [95% confidence interval, 1.07–2.40]). However, net clinical outcome integrating these 
2 end points (efficacy and safety) was improved with vorapaxar (hazard ratio, 0.79 [95% confidence interval, 0.67–0.93]).
Conclusions—In patients with previous MI and DM, the addition of vorapaxar to standard therapy significantly reduced the 
risk of major vascular events with greater potential for absolute benefit in this group at high risk of recurrent ischemic 
events.
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Antithrombotic therapies, such as glycoprotein IIb/IIIa antag-
onists, enoxaparin, and prasugrel, have shown a consistent 
pattern of greater absolute and, in some cases, greater relative 
benefit in patients with DM compared with patients without 
this condition.7–10
Vorapaxar is a first-in-class protease-activated receptor-1 
antagonist that potently inhibits thrombin-induced activation 
of platelets. Vorapaxar is effective for secondary prevention in 
patients with a history of atherosclerosis while increasing mod-
erate or severe bleeding.10,11 Because of this tradeoff in poten-
tial benefit versus risk, it is of interest to identify patients, in 
particular among those with a history of myocardial infarction 
(MI), who may be appropriate candidates for treatment with 
vorapaxar.11 Therefore, in the present analysis, we examined 
the efficacy and safety of vorapaxar for secondary prevention 
of cardiovascular (CV) events in patients with and without DM 
who were enrolled in a large, randomized trial of vorapaxar 
versus placebo in the 2 weeks to 1 year after a qualifying MI.
Methods
Study Population
We have previously reported the design and results of the multina-
tional, randomized, double-blind, placebo-controlled trial of vorapaxar 
for secondary prevention of atherothrombosis (Thrombin Receptor 
Antagonist in Secondary Prevention of Atherothrombotic Ischemic 
Events-TIMI 50 [TRA 2°P-TIMI 50]).12,13 As reported previously, 
17 779 patients qualified for the TRA 2°P-TIMI 50 trial on the basis 
of a history of MI within 2 weeks to 12 months and were randomly 
assigned to treatment with either vorapaxar sulfate 2.5 mg daily or pla-
cebo. Key exclusion criteria included a high risk of bleeding (history of 
a bleeding diathesis, recent active bleeding, or treatment with a vitamin 
K antagonist) or active hepatobiliary disease. Vorapaxar is approved 
for clinical use in the United States but is contraindicated in patients 
with a history of transient ischemic attack (TIA) or stroke. We there-
fore focused this analysis on the population of 16 896 patients with a 
history of a qualifying MI but without a history of stroke or TIA who 
are eligible for vorapaxar and relevant to clinical practice. Data for the 
broader population approved for clinical use in the United States (MI 
and peripheral arterial disease with no previous stroke or TIA) are pro-
vided (Tables I and II in the online-only Data Supplement).
The institutional review board or ethics committee for each par-
ticipating institution trial reviewed and approved the trial. All of the 
patients gave written informed consent.
End Points
The primary end point for this analysis was the composite of CV 
death, MI, or stroke.13 The key secondary end point was the com-
posite of the primary end point or recurrent ischemia leading to 
urgent revascularization. Bleeding was classified using the Global 
Utilization of Streptokinase and t-PA for Occluded Coronary Arteries 
(GUSTO) definition.14 A blinded clinical events committee adjudi-
cated all elements of the primary and secondary efficacy end points, 
as well as all bleeding events in the trial.
Statistical Methods
A prespecified analysis was performed based on the patient’s history 
of DM as recorded by the local investigator at the time of random 
assignment. Comparisons of baseline characteristics between patients 
with and without DM were made using the χ2 test for categorical vari-
ables and the Wilcoxon rank-sum test for continuous variables. A Cox 
proportional hazard model was used for the efficacy analyses with 
the investigational treatment allocation and planned use of a thieno-
pyridine as covariates. The interaction of DM with the randomized 
treatment was assessed in the overall US approval cohort with the 
addition of an interaction term (DM × treatment allocation) to the 
Cox proportional hazard model along with each of the main effects. 
Interaction P values <0.10 were considered evidence of a possible 
interaction. Kaplan-Meier 3-year cumulative event rates are presented 
with patients censored at the occurrence of an end point, death, or at 
the time of the last visit. Absolute risk differences and associated con-
fidence intervals were generated using the risk reductions and confi-
dence boundaries from the Cox model. Analyses of bleeding were 
performed in patients who received 1 or more doses of study drug. 
These analyses included all of the events that occurred from the first 
dose of study drug until 30 days after a final visit at the conclusion of 
the trial or 60 days after premature drug discontinuation.13
A Cox proportional hazard survival model was developed to 
describe the association between DM and the risk of CV death, MI, 
or stroke. Given the differences in patients with and without DM, the 
model included covariates that were thought to be potential confound-
ers a priori (treatment allocation, age, sex, race, history of hyperten-
sion, history of hyperlipidemia, ongoing tobacco abuse, history of 
peripheral arterial disease, history of stroke or TIA, history of con-
gestive heart failure, creatinine clearance <60 mL/min, weight <60 
kg, and region). The proportional hazard assumption was tested using 
visual inspection of the Schoenfeld residuals. Analyses were per-
formed with Stata version 12.1 (StataCorp LP, College Station, TX).
Results
Among the 16 896 patients with a previous MI and no previ-
ous stroke or TIA randomly assigned to vorapaxar or placebo, 
3623 (21%) had DM. Patients with DM were older, more often 
women, and were more likely to have hypertension, peripheral 
arterial disease, renal dysfunction, and obesity (Table 1). The 
majority (84%) of the patients with DM were being treated 
with either insulin or noninsulin therapies for hyperglycemia. 
Evidenced-based therapies for secondary prevention of ath-
erothrombosis were used in a high proportion of both patients 
with and without DM (Table 1). The baseline characteristics in 
patients with and without DM stratified by treatment allocation 
were similar (Table III in the online-only Data Supplement).
CV Outcomes and Bleeding in DM
Among placebo-allocated patients, those with DM, when 
compared with those without, had nearly double the incidence 
of CV death, MI, or stroke at 3 years (14.3% versus 7.6%; 
P<0.001). After adjusting for potential confounders (treatment 
allocation, age, sex, race, history of hypertension, history of 
hyperlipidemia, ongoing tobacco abuse, history of peripheral 
arterial disease, history of stroke or TIA, history of congestive 
heart failure, creatinine clearance <60 mL/min, weight <60 kg, 
and region), DM was still associated with a 47% higher risk 
of CV death, MI, or stroke (adjusted hazard ratio [HR
adj], 1.47 
[95% confidence interval {CI}, 1.24–1.75]; P<0.001; Figure 1). 
Patients with DM were also at increased risk of the individual 
end points of CV death (4.4% versus 1.7%; HR
adj, 1.58 [95% 
CI, 1.13–2.21]; P=0.008) and recurrent MI (10.2% versus 
5.6%; HR
adj, 1.46 [95% CI, 1.20–1.79]; P<0.001), with a trend 
toward a higher risk of stroke (2.5% versus 1.1%; HR
adj, 1.54 
[95% CI, 1.00–2.37]; P=0.051). The risk of GUSTO moderate/
severe bleeding was similar in patients with and without DM 
(2.6% versus 1.9%; HR
adj, 0.93 [95% CI, 0.63–1.38]; P=0.72).
Efficacy and Safety of Vorapaxar
In patients with DM, treatment with vorapaxar reduced CV 
death, MI, or stroke at 3 years by 27% (hazard ratio [HR], 0.73 
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[95% CI, 0.60–0.89]; P=0.002; Figure 2). Similar effects were 
observed both in patients with DM treated with insulin (HR, 
0.74 [95% CI, 0.53–1.02]) or without insulin (HR, 0.71 [95% 
CI, 0.56–0.92]; P for interaction=0.90). The relative effect 
of vorapaxar was similar among patients without DM (HR, 
0.81 [95% CI, 0.71–0.93]; P=0.003; P for interaction=0.40). 
However, because the rate of major CV events was substantially 
higher in patients with DM, treatment with vorapaxar had a 
pattern of greater absolute risk reduction in patients with DM 
(absolute risk difference, –3.50% [95% CI, –1.28 to –5.36]) than 
without DM (absolute risk difference, –1.36% [95% CI, –0.45 to 
–2.15]). The calculated number needed to treat to avoid 1 major 
CV event over 3 years was 29 (95% CI, 19–78) among patients 
with DM and 74 (95% CI, 46–223) among those without DM.
This pattern of a consistent relative risk reduction and 
greater absolute benefit in patients with DM was apparent 
across all components of the primary end point (Table 2). 
The relative effect of vorapaxar on ischemic end points was 
nominally greater in patients with than without DM, including 
recurrent ischemia leading to urgent revascularization (P for 
interaction=0.02) and coronary revascularization with either 
percutaneous coronary intervention or coronary artery bypass 
graft surgery (P for interaction=0.008; Figure 3).
An increase in moderate or severe bleeding with vorapaxar 
in patients with DM (4.4% versus 2.6%; HR, 1.60 [95% CI, 
1.07–2.40]) was similar to that for patients without DM (P 
for interaction=0.93; Table 3). Two prespecified composite 
end points of net clinical outcome were evaluated (Table 3). 
Among patients with DM, vorapaxar improved the net clinical 
outcome of CV death, MI, stroke, or recurrent ischemia lead-
ing to revascularization plus GUSTO moderate/severe bleed-
ing (HR, 0.79 [95% CI, 0.67–0.93]; P=0.005), as well as the 
composite of death, MI, stroke, or GUSTO severe bleeding 
(HR, 0.77 [95% CI, 0.65–0.93]). Notably, the absolute risk dif-
ference for CV death, MI, stroke, recurrent ischemia requiring 
urgent revascularization, or GUSTO moderate/severe bleed in 
patients with DM was –3.89% (95% CI, –1.34 to –6.11) and in 
those without DM was –0.53% (95% CI, 0.61 to –1.57).
Discussion
Vorapaxar is a novel platelet inhibitor that is effective for 
the secondary prevention of atherothrombosis. As with other 
potent antiplatelet agents, its clinical use should take into 
account an individualized assessment of the potential anti-
thrombotic benefits and risk of bleeding. Our findings from 
the TRA2°P-TIMI 50 trial showed a higher risk of recurrent 
major CV events in diabetic versus nondiabetic patients with 
established atherosclerosis despite standard medical therapy. 
When added to these standard therapies, treatment with vora-
paxar reduced CV death, MI, or stroke in this high-risk group. 
Because of their higher cumulative risk, patients with DM had 
a potential greater absolute risk reduction than patients with-
out DM, which translates into fewer patients needed to treat to 
prevent a major CV event (Figure 2).
Table 1. Baseline Demographics Stratified by Diabetes 
Mellitus (DM) at Randomization
Demographics
DM
(n=3623)
No DM
(n=13273) P Value
Median age (25%, 75%), y 61 (54, 68) 58 (50, 65) <0.001
Women, n (%) 956 (26.4) 2443 (18.4) <0.001
Body mass index ≥30, n (%) 1719 (47.5) 3735 (28.2) <0.001
Hypertension, n (%) 2847 (78.6) 7540 (56.8) <0.001
Hyperlipidemia, n (%) 3287 (90.7) 10 979 (82.7) <0.001
Current tobacco abuse, n (%) 624 (17.2) 2704 (20.4) <0.001
Peripheral arterial disease, n (%) 536 (14.8) 872 (6.6) <0.001
History of heart failure, n (%) 545 (15.0) 870 (6.6) <0.001
Previous PCI/CABG, n (%) 3090 (85.3) 11 458 (86.3) 0.10
Baseline GFR <60 mL/min per 
1.73 m2, n (%)
678 (19.0) 1297 (9.9) <0.001
Baseline medications, n (%)
  Aspirin 3544 (98) 13 068 (98) 0.01
  Thienopyridine 2706 (74.7) 10 528 (79.3) <0.001
  Lipid-lowering agent 3480 (96.1) 12 835 (96.7) 0.06
  ACEi/ARB 3092 (85.3) 10 019 (75.5) <0.001
Baseline diabetes mellitus therapy, n (%)
  Lifestyle modifications 587 (16.2) NA
  Noninsulin therapy 921 (25.4) NA
  Insulin therapy 2114 (58.4) NA
ACEi indicates angiotensin-converting-enzyme inhibitor; ARB, angiotensin II 
receptor blocker; CABG, coronary artery bypass graft surgery; GFR, glomerular 
filtration rate; NA, not applicable; and PCI, percutaneous coronary intervention. 
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Figure 1. Incidence of cardiovascular (CV) death, 
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diabetes mellitus status (placebo group only). KM 
indicates Kaplan-Meier.
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DM and Secondary Prevention
Patients with established atherosclerosis who have DM have 
a high residual risk of recurrent events despite treatment with 
intensive medical therapy.15–18 This increased risk is related to 
the high prevalence of other risk factors in patients with DM 
(eg, hypertension and obesity), as well as the direct adverse 
pathological consequences of DM, including endothelial dys-
function, vascular inflammation, abnormal platelet reactivity, 
and decreased responsiveness to commonly used therapies.19 
Notably, we found that, after adjusting for potential confound-
ers, despite the use of aspirin in 98%, lipid-lowering agents 
in 97%, and renin-angiotensin pathway antagonists in 78%, 
patients with DM were still at 47% increased risk of major 
CV events. As the prevalence of DM increases, the second-
ary prevention of atherothrombosis will assume heightened 
importance in this high-risk group.
Vorapaxar and Secondary Prevention
In light of the increased reactivity of platelets that contrib-
utes to the adverse CV outcomes in patients with DM,6 this 
group of patients was identified at the initiation of TRA 
2°P-TIMI 50 as a population of particular interest.6,18,20 
We have shown previously that potent inhibition of the 
platelet P2Y12 receptor pathway with prasugrel in patients 
Table 2. Efficacy of Vorapaxar in Patients With and Without Diabetes Mellitus
Variable
Diabetes Mellitus No Diabetes Mellitus
Vorapaxar  
Event Rate 
(n=1809), %
Placebo  
Event Rate 
(n=1814), % HR (95% CI) P Value
Vorapaxar  
Event Rate 
(n=6648), %
Placebo  
Event Rate 
(n=6625), % HR (95% CI) P Value
P Value  
(int)
CVD, MI, or stroke 11.4 14.3 0.73 (0.60–0.89) 0.002 6.3 7.6 0.81 (0.71–0.93) 0.003 0.40
CV death 3.9 4.4 0.87 (0.61–1.23) 0.43 1.4 1.7 0.79 (0.58–1.07) 0.12 0.67
MI 8.1 10.2 0.74 (0.59–0.94) 0.01 4.7 5.6 0.83 (0.71–0.98) 0.02 0.44
Stroke 1.4 2.5 0.53 (0.30–0.92) 0.02 0.8 1.1 0.67 (0.46–0.98) 0.04 0.49
Death 5.9 6.6 0.88 (0.67–1.16) 0.36 2.7 2.9 0.94 (0.76–1.18) 0.59 0.70
CVD or MI 10.6 12.6 0.77 (0.63–0.95) 0.01 5.8 6.9 0.83 (0.71–0.96) 0.01 0.58
CVD, MI, stroke, or 
recurrent ischemia-urgent 
revascularization
14.5 18.0 0.73 (0.61–0.87) <0.001 8.6 9.6 0.86 (0.76–0.97) 0.02 0.12
CVD, MI, stroke, or 
recurrent ischemia-
urgent revascularization, 
or hospitalization for 
unstable angina
15.7 19.7 0.75 (0.63–0.88) <0.001 9.8 10.6 0.89 (0.80–1.00) 0.05 0.08
 Recurrent ischemia-
urgent revascularization
4.0 5.5 0.63 (0.45–0.88) 0.006 2.8 2.6 1.01 (0.81–1.26) 0.91 0.02
 Hospitalization for 
unstable angina
5.6 7.6 0.69 (0.53–0.91) 0.009 4.2 3.8 1.03 (0.86–1.23) 0.73 0.02
 Coronary 
revascularization
14.3 17.6 0.75 (0.63–0.90) 0.002 10.7 10.8 1.00 (0.89–1.11) 0.95 0.008
CI indicates confidence interval; CV, cardiovascular; CVD, cardiovascular disease; HR, hazard ratio; int, interaction; and MI, myocardial infarction.
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Figure 2. Incidence of cardiovascular death, 
myocardial infarction, or stroke with vorapaxar vs 
placebo stratified by diabetic status. ARD indicates 
absolute risk difference; HR, hazard ratio; and NNT, 
number needed to treat.
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presenting with an acute coronary syndrome offers a greater 
benefit in patients with DM compared with nondiabetics.9 
Similarly, patients with hemoglobin A1c ≥6% had evi-
dence of a greater benefit from treatment with ticagrelor.18 
Our data raise the possibility that vorapaxar, which inhib-
its platelets via a pathway separate from that of aspirin and 
P2Y12 inhibitors, similarly offers a particular advantage for 
patients with DM.
First, we found that there was a consistent reduction in 
major CV events with vorapaxar added to standard therapy 
among patients with DM. Second, because of their higher 
rate of recurrent CV events, patients with DM had a higher 
absolute risk reduction and a number needed to treat of 29 
compared with 74 in patients without diabetes mellitus. 
Third, a nominal treatment interaction was observed such 
that, compared with patients without DM, patients with 
1 1.20.5 0.6 0.7 0.8 0.90.4
MI
DM-
DM+
PCI/CABG
DM-
DM+
KM (%) HR 95% CI Interactionp-value
4.7 0.83 (0.71-0.98)
8.1
14.3
10.7
0.74 (0.59-0.94)
1.00 (0.89-1.11)
0.75 (0.63-0.90)
V P
0.44
RIUR
DM-
DM+ 4.0
2.8 1.01  (0.81-1.26)
0.63 (0.45-0.88)
0.02
UA
DM-
DM+ 5.6
4.2 1.03 (0.86-1.23)
0.69 (0.53-0.91)
0.02
0.008
10.2
5.6
3.8
7.6
2.6
5.5
17.6
10.8
Hazard Ratio (95% CI) for Vorapaxar vs. Placebo
Figure 3. Effects of vorapaxar on ischemic events stratified by diabetes mellitus (DM) status. CABG indicates coronary artery bypass graft 
surgery; CI, confidence interval; HR, hazard ratio; KM, Kaplan–Meier; MI, myocardial infarction; PCI, percutaneous coronary intervention; 
RIUR, recurrent ischemia leading to urgent revascularization; and UA, unstable angina.
Table 3.  Bleeding and Net Clinical Outcomes in Patients With and Without Diabetes Mellitus
Variable
Diabetes Mellitus No Diabetes Mellitus
Vorapaxar  
Event Rate  
(n= 1805), %
Placebo  
Event Rate 
(n=1808), % HR (95% CI) P Value
Vorapaxar  
Event Rate  
(n= 6638), %
Placebo  
Event Rate  
(n= 6604), % HR (95% CI) P Value
Bleeding
GUSTO moderate or 
severe bleed
4.4 2.6 1.60 (1.07–2.40) 0.02 2.9 1.9 1.56 (1.22–2.00) <0.001
  GUSTO severe bleed 1.5 1.0 1.28 (0.65–2.51) 0.48 1.1 1.0 1.21 (0.83–1.76) 0.32
  GUSTO moderate bleed 2.9 1.7 1.70 (1.04–2.79) 0.04 1.9 1.0 1.92 (1.39–2.66) <0.001
 TIMI clinically significant 
bleed (TIMI major/minor/
medical attention)
17.1 11.4 1.50 (1.24–1.82) <0.001 14.4 9.9 1.50 (1.35–1.67) <0.001
 TIMI major bleed 2.5 1.9 1.11 (0.68–1.82) 0.68 2.2 1.7 1.31 (1.00–1.72) 0.051
 TIMI minor bleed 2.1 0.7 2.79 (1.44–5.41) 0.002 1.2 0.5 2.32 (1.50–3.59) <0.001
Fatal bleed 0.4 0.3 1.00 (0.20–4.97) >0.99 0.2 0.1 1.67 (0.61–4.60) 0.32
ICH 0.9 0.7 1.23 (0.51–2.97) 0.65 0.5 0.4 1.59 (0.87–2.92) 0.13
Net clinical outcomes
CV death, MI, stroke, 
RIUR, or GUSTO moderate/
severe bleed
16.7 19.6 0.79 (0.67–0.93) 0.005 10.4 10.9 0.95 (0.85–1.06) 0.32
Death, MI, stroke, or 
GUSTO severe bleed
13.6 16.4 0.77 (0.65–0.93) 0.006 8.2 9.2 0.88 (0.77–0.99) 0.04
Event rates are presented as 3-year Kaplan–Meier estimates. The P values for the interaction between the effects of vorapaxar vs placebo in those with and without 
diabetes mellitus were all ≥0.05. CI indicates confidence interval; CV, cardiovascular; GUSTO, Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries; 
HR, hazard ratio; ICH, intracerebral hemorrhage; MI, myocardial infarction; RIUR, recurrent ischemia leading to urgent revascularization; and TIMI, thrombolysis in 
myocardial infarction.
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DM had a significantly greater relative reduction in hospi-
talization for unstable angina or coronary revascularizations. 
Although exploratory in nature, this observation that more 
potent antithrombotic therapy with vorapaxar provided a 
more pronounced reduction in ischemic events is consistent 
with what is known about the platelet pathobiology, as well 
as previous studies of antithrombotic agents in patients with 
DM (eg, patients treated with glycoprotein IIb/IIIa inhibitors 
at the time of acute coronary syndrome).7 In light of these 
findings, when weighing the risk of bleeding with the anti-
thrombotic benefits of vorapaxar, patients with DM appear to 
be particularly appropriate candidates for consideration for 
treatment with this new therapy.
Limitations
These findings should be considered in the context of the 
limitations of the study. First, our observations are based on 
subgroups in the overall trial. However, this analysis was 
prespecified and the subgroups were large. Patients with DM 
can differ in the duration of the disease, degree of glycemic 
control, and presence of other medical comorbidities. Given 
the randomized nature of the study, these characteristics were 
likely balanced between the vorapaxar and placebo groups 
and thus not expected to influence the treatment comparison. 
However, it is possible that the magnitude of our observed 
effect may not apply to the entire spectrum of manifesta-
tions of DM. Second, the nominally significant interaction in 
the efficacy of vorapaxar with regard to ischemic end points 
should be regarded as hypothesis generating. Third, because 
the data were not captured in this trial, we are unable to per-
form additional exploratory analyses based on glycemic con-
trol or length of time in which patients have had DM.
Conclusions
Vorapaxar is an additional treatment option for long-term sec-
ondary prevention in patients with DM who have had a previ-
ous MI, in the absence of a previous stroke or TIA. DM is a 
high-risk indicator that identifies patients who appear to have 
a particularly favorable balance of antithrombotic efficacy and 
bleeding with vorapaxar.
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CLINICAL PERSPECTIVE
Vorapaxar is a first-in-class inhibitor of the platelet protease-activated receptor-1 pathway that is activated by thrombin. 
Vorapaxar is established to be effective for the secondary prevention of atherothrombosis and, like other potent antiplatelet 
agents, increases bleeding. The findings from this analysis of the TRA2°P-TIMI 50 show that, in high-risk patients with 
diabetes mellitus, the addition of vorapaxar to standard therapy significantly reduced the risk of cardiovascular death, myo-
cardial infarction, or stroke with a favorable effect on net clinical outcomes. Although the relative benefit of vorapaxar was 
similar in patients with or without diabetes mellitus, there was a greater absolute risk reduction in cardiovascular events with 
vorapaxar in patients with diabetes mellitus such that only 29 patients needed to be treated to prevent one occurrence of 
cardiovascular death, myocardial infarction, or stroke over the period of follow-up (3 years). The use of vorapaxar in clini-
cal practice should weigh the potential reductions in ischemic events with the concomitant risk of bleeding. These findings 
indicate that patients with diabetes mellitus have a particularly favorable balance between the risk of bleeding and reduction 
in thrombotic events with vorapaxar.
